Mr. Chien Huang reports

INDEPENDENT PROXY ADVISOR, INSTITUTIONAL SHAREHOLDER SERVICES ("ISS"), RECOMMENDS TITAN SHAREHOLDERS VOTE FOR THE AMALGAMATION BETWEEN TITAN AND CONAVI

Institutional Shareholder Services (ISS) has released a report recommending that Titan Medical Inc.'s shareholders vote in favour of the proposed amalgamation with Conavi Medical Inc. to be approved by the shareholders at the annual general and special meeting of Titan to be held on Sept. 30, 2024.

As an independent proxy advisory firm, ISS has approximately 3,400 clients including many of the world's leading institutional investors who rely on ISS's objective and impartial analysis to make important voting decisions.

In reaching its recommendation that shareholders vote for the amalgamation, ISS stated in its report: "The proposed amalgamation makes strategic sense as it appears to represent the best alternative among the opportunities available to improve the ability to increase shareholder value, and it is anticipated the transaction will enhance value for shareholders through ownership in a company with growth potential, with an improved balance sheet, and is expected to benefit from reduced listing requirements associated with relisting on the [TSX Venture Exchange]."

"We are pleased that after reviewing the proposed business combination that ISS is recommending all shareholders vote for the amalgamation," said Paul Cataford, Titan's interim chief executive officer and board chairman. "This independent analysis and recommendation further validates the Titan board's unanimous decision to recommend the amalgamation transaction with Conavi Medical Inc."

Vote today

Don't delay. Your vote matters no matter how many shares you own. Please vote by Sept. 26, 2024, at 4 p.m. ET.

Shareholder questions and assistance

Shareholders who have any questions about the meeting, or require assistance with voting, may contact Shorecrest Group by telephone at 1-888-637-5789 or 1-647-931-7454 (bankers and brokers/collect calls outside North America), or by e-mail at contact@shorecrestgroup.com.

About Titan Medical Inc.

Titan Medical, a medical technology company incorporated under the Business Corporations Act (Ontario) and headquartered in Toronto, Ont., has developed an expansive patent portfolio related to the enhancement of robotic assisted surgery (RAS), including through a single access point, and is currently focused on evaluating new opportunities to further develop and license its intellectual property.

About Conavi Medical Inc.

Conavi Medical is a privately owned company focused on designing, manufacturing and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. Its patented Novasight Hybrid system is the first system to combine both IVUS (intravascular ultrasound) and OCT (optical coherence tomography) to enable simultaneous and co-registered imaging of coronary arteries. The Novasight Hybrid system has 510(k) clearance from the U.S. Food and Drug Administration; and regulatory approval for clinical use from Health Canada, China's National Medical Products Administration, and Japan's Ministry of Health, Labor and Welfare.

We seek Safe Harbor.